Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 8/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | TTR | P02766 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.47 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.47 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10952727 | 0.85 | CXCL8 (0.53) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL6256539 | 0.84 | CXCL8 (0.53) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL10651614 | 0.84 | CXCL8 (0.64) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL11093807 | 0.82 | CXCL8 (0.58) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL29845650 | 0.81 | TSHR (0.48) | CXCL8LMNAKMT2ACYP3A4TSHR | |
| SCHEMBL8069967 | 0.81 | TSHR (0.48) | CXCL8LMNAKMT2ACYP3A4TSHR | |
| SCHEMBL19451943 | 0.81 | TSHR (0.48) | CXCL8LMNAKMT2ACYP3A4TSHR | |
| SCHEMBL29973372 | 0.81 | TSHR (0.48) | CXCL8LMNAKMT2ACYP3A4TSHR | |
| SCHEMBL3137707 | 0.79 | CXCL8 (1.00) | CXCL8PTGS2TTRPTGS1AKR1B10 | |
| SCHEMBL12129515 | 0.79 | CXCL8 (1.00) | CXCL8PTGS2TTRPTGS1AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005073163-A1 | A PROCESS FOR THE PREPARATION OF [2-(2,6-DICHLORO ANILINO) PHENYL] ACETOXY ACETIC ACID | J.B.CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2005-08-11 | — | — | WO | claimed |
| US-4548952-A | ANTINFLAMMATORY, ANALGESIC AGENTS | PRODES, S.A. (ES) | 1985-10-22 | — | — | US | claimed |
| JP-63063647-A | — | — | None | — | — | JP | disclosed |
| EP-3838270-B1 | SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALISED FORMS OF RHEUMATIC ILLNESSES | AMEZCUA AMEZCUA FEDERICO (MX) | 2024-10-09 | — | — | EP | disclosed |
| US-20210228598-A1 | SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALISED FORMS OF RHEUMATIC ILLNESSES | Amezcua Amezcua, Federico (MX) | 2021-07-29 | — | — | US | disclosed |
| EP-3838270-A2 | SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALISED FORMS OF RHEUMATIC ILLNESSES | Amézcua Amézcua, Federico (MX) | 2021-06-23 | — | — | EP | disclosed |
| EP-2393486-A1 | ACECLOFENAC-CONTAINING CONTROLLED-RELEASE ORAL DRUG PREPARATIONS AND THEIR MANUFACTURING PROCESS | Korea United Pharm, Inc. (KR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090371-A1 | ACECLOFENAC-CONTAINING CONTROLLED-RELEASE ORAL DRUG PREPARATIONS AND THEIR MANUFACTURING PROCESS | KOREA UNITED PHARM, INC (KR) | 2010-08-12 | — | — | WO | disclosed |
| EP-1814517-B1 | NONAQUEOUS LIQUID PARENTERAL ACECLOFENAC FORMULATION | VENUS REMEDIES LTD (IN) | 2010-08-11 | — | — | EP | disclosed |
| WO-2010008135-A1 | ORAL SOFT CAPSULE OF ACECLOFENAC HAVING IMPROVED STABILITY | KOREA UNITED PHARM, INC (KR) | 2010-01-21 | — | — | WO | disclosed |
| US-20090156670-A1 | NONAQUEOUS LIQUID PARENTERAL ACECLOFENAC FORMULATION | VENUS REMEDIES LIMITED (IN) | 2009-06-18 | — | — | US | disclosed |
| WO-2005073163-A1 | A PROCESS FOR THE PREPARATION OF [2-(2,6-DICHLORO ANILINO) PHENYL] ACETOXY ACETIC ACID | J.B.CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073163-A1 | A PROCESS FOR THE PREPARATION OF [2-(2,6-DICHLORO ANILINO) PHENYL] ACETOXY ACETIC ACID | J.B.CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2005-08-11 | — | — | WO | disclosed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | disclosed |
| US-5844696-A | Nitric esters from derivatives of 2-(2,6-dihalophenylamino) phenylacetoxyacetic acid and their preparation process | PRODES, S.A. (ES) | 1998-12-01 | — | — | US | disclosed |
| EP-0738706-B1 | Nitric esters of 2-(2,6-dihalophenylamino) phenylacetoxyacetic acid derivatives and their preparation process | PRODES SA (ES) | 1998-10-07 | — | — | EP | disclosed |
| EP-0738706-A1 | Nitric esters of 2-(2,6-dihalophenylamino) phenylacetoxyacetic acid derivatives and their preparation process | PRODES, S.A. (ES) | 1996-10-23 | — | — | EP | disclosed |
| JP-S6363647-A | NOVEL 2-((2,6-DICHLOROPHENYL)AMINO)PHENYLACETOXYACETIC ACID DERIVATIVE | UJI SEIYAKU KK | 1988-03-22 | — | — | JP | disclosed |
| EP-0119932-B1 | NEW 2-((2,6-DICHLOROPHENYL)AMINE)PHENYLACETOXYACETYL DERIVATIVES, THE PROCESS FOR PREPARING THE SAME AND THEIR USE IN THERAPEUTICS | PRODES S.A. (ES) | 1987-05-13 | — | — | EP | disclosed |
| US-4548952-A | ANTINFLAMMATORY, ANALGESIC AGENTS | PRODES, S.A. (ES) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228598-A1 | SYNERGISTIC PHARMACEUTICAL COMPOSITION COMPRISING ACECLOFENAC AND BETAMETHASONE FOR THE TREATMENT OF PAIN IN LOCALISED FORMS OF RHEUMATIC ILLNESSES | ACE, ACE2, TSLP | CXCL8 1393/4885PTGS2 791/4885TTR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.